Dana-Farber, Mass General Brigham, and Broad Institute researchers uncovered clues to why colorectal cancer can be more aggressive in younger people.

First results from the phase 2 AZUR-1 trial showed sustained clinical complete responses with dostarlimab alone, sparing most patients chemoradiation and surgery.

Updated GOBLET cohort 4 data showed a median DOR of about 15 months with pelareorep plus atezolizumab in second-line or later anal cancer.

The top 5 OncLive TV videos of the week cover insights in CRC at ESMO 2026, dMMR rectal cancer, chronic neutropenia, pediatric LGG, and MSS CRC.